Emiliya Melkumova, MD
Vascular Neurology · Boston, MANPI 1962740472
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,825 of the $15,070 with a category attached, or 78.5%. Bayer accounts for 89.4% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $10,950 and has fallen 77.3% since, to $2,485 in 2025.
Across 82 payments — averaging $183.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$13K
- Sunovion Pharmaceuticals Inc.$510
- Carestream Dental, LLC$206
- Teva Pharmaceuticals USA, Inc.$185
- Microtransponder, Inc.$137
- AbbVie$101
- plus $463 from 14 others
What the payments were for
- Consulting fees$11,82578%
- Speaking & faculty fees$130%
- Travel & lodging$9626%
- Food & beverage$2,27115%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 21 | $13,468 |
| Sunovion Pharmaceuticals Inc. | 22 | $510 |
| Carestream Dental, LLC | 1 | $206 |
| Teva Pharmaceuticals USA, Inc. | 9 | $185 |
| Microtransponder, Inc. | 1 | $137 |
| AbbVie | 6 | $101 |
| CSL Behring | 4 | $85 |
| Portola Pharmaceuticals, LLC | 2 | $62 |
| Amgen | 2 | $53 |
| AstraZeneca | 2 | $43 |
| Amneal Pharmaceuticals LLC | 2 | $39 |
| UCB, Inc. | 1 | $32 |
| Chiesi USA, Inc. | 2 | $26 |
| Grifols USA, LLC | 1 | $22 |
| Boston Scientific | 1 | $21 |
| Pfizer | 1 | $20 |
| GE HealthCare | 1 | $19 |
| EMD Serono, Inc. | 1 | $17 |
| Acorda Therapeutics, Inc | 1 | $13 |
| Novocure Inc. | 1 | $12 |
How this compares
Too few vascular neurology providers in Massachusettsto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 14 | $9,646 |
| Cilostazol | 17 | $855 |
| Atorvastatin Calcium | 31 | $745 |
| Duloxetine Hcl | 17 | $99 |
| Nortriptyline Hcl | 12 | $67 |
Paid to pharmacies, not to this prescriber.
Other vascular neurology in Boston
- Mariel KozbergBoston$6K
- Magdy SelimBoston$6K
- David GreerBoston$3K
- Vasileios Arsenios LioutasBoston$412
- Gustavo CarvajalBoston$322
- Elizabeth RosenBoston$102
- Anusha NallaparajuBoston$47
- Neal ParikhBoston$30
- Janhavi ModakSpringfield$7K
- Jose Marino GranadosWorcester$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.